IL21 monoclonal antibody, clone SB134f
- Known as:
- IL21 mab (anti-), clonality SB134f
- Catalog number:
- MAB8557
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- IL21 monoclonal antibody clone SB134f
Related genes to: IL21 monoclonal antibody, clone SB134f
- Gene:
- IL21 NIH gene
- Name:
- interleukin 21
- Previous symbol:
- -
- Synonyms:
- Za11, IL-21
- Chromosome:
- 4q27
- Locus Type:
- gene with protein product
- Date approved:
- 2000-03-29
- Date modifiied:
- 2019-04-23
Related products to: IL21 monoclonal antibody, clone SB134f
Related articles to: IL21 monoclonal antibody, clone SB134f
- Arsenic (As) is an extremely hazardous trace metalloid frequently found in water bodies, where it poses substantial threats to all living organisms, including fish. Its removal has therefore become a significant global challenge. - Source: PubMed
Publication date: 2026/09/30
Habotta Ola ARawan Ahmad FAbdelmoneim DoaaAdly Mina SAteya AhmedIbrahim ImanAmer ShroukAzab Rasha EHabak SaraMorsi RehabHetta Helal FIbrahim Samah FShukry MustafaEl-Nemr AhmedRaia AmrAbdeen Ahmed - This study aimed to characterize the distributions of Th17 and regulatory T (Treg) cells and the associated interleukin-21 (IL-21) signaling in patients with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (Mtb) coinfection. - Source: PubMed
Publication date: 2026/09/25
Chen GaoChen Shikai - Hepatocellular carcinoma (HCC) remains a significant global health threat characterized by aggressive progression and high mortality rates. Despite therapeutic advancements, survival for advanced stages is unacceptably low, necessitating innovative approaches like Natural Killer (NK) cell-based immunotherapy. NK cells are crucial innate immune components providing rapid tumor cytotoxicity without prior sensitization. However, the HCC tumor microenvironment (TME) presents a formidable barrier, inducing NK cell dysfunction through immunosuppressive cytokines like TGF-[Formula: see text], chronic hypoxia, and metabolic exhaustion driven by lipid accumulation. This literature review consolidates and integrates findings regarding current NK cell-based strategies in HCC, with particular emphasis on mechanisms of NK cell dysfunction within the TME and therapeutic approaches designed to restore their antitumor activity. Emerging therapeutic strategies involve cytokine-supported approaches, including the adoptive transfer of autologous or allogeneic NK cells expanded ex vivo using stimuli such as IL-15 and IL-21. In parallel, advances in genetic engineering have enabled the development of modified NK cells, including chimeric antigen receptor (CAR)-NK platforms targeting HCC-associated antigens such as glypican-3 (GPC3) and CD147 and bispecific and trispecific killer cell engagers (BiKEs and TriKEs). This review underscores the translational potential of NK cell-based therapies by highlighting unresolved knowledge gaps in the complex interplay between NK cells and the TME. These developments provide a foundation for optimizing NK cell immunotherapy and improving prognostic outcomes for patients with HCC. - Source: PubMed
Publication date: 2026/09/24
Widowati WahyuWargasetia Teresa LilianaSadri BaharehNainggolan Ita MargarethaAzis RizalRifana Safira DindaRismani ElhamVosough Massoud - Precision-cut lymph node slices (PCLNS) provide a physiologically relevant ex vivo model to investigate lymphoid immune activation and vaccine adjuvant function while preserving native tissue architecture. In this study, we established for the first time porcine PCLNS and assessed the immunostimulatory capacity of PCLNS to Toll-like receptor (TLR) 7/8 agonist (Resiquimod; R848) alone or in combination with porcine circovirus type 2 (PCV2) or PCV2 virus-like particles (VLPs). - Source: PubMed
Publication date: 2026/09/09
Deosthali SamruddhiMarti-Garcia BernatHarris HeatherWerling NatalieNoad RobertGerner WilhelmWerling Dirk - Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance is common. We modeled KRASi response and relapse in mice and demonstrated that, unlike chemotherapy or combinations with checkpoint blockade, an interleukin (IL)-21 cytokine mimic (21h10) induced long-term, durable remissions. Its efficacy depends on T helper 1 (Th1)-polarized CD4 T cells, but not on CD8 T cells or tumor cell expression of major histocompatibility complex class I (MHC class I). Specifically, CD4 T cells primed by type 2 conventional dendritic cells (cDC2s) produce interferon γ (IFN-γ), which promotes macrophage-mediated phagocytosis of tumor cells. Ex vivo treatment of human PDAC specimens with 21h10 induces IFN-γ production by infiltrating T cells. Thus, IL-21-elicited CD4 T cells exert antitumor activity in mice and potentially in humans, converting transient responses to KRAS inhibition into durable remissions. - Source: PubMed
Publication date: 2026/09/23
Qiang LiHoffman Megan TChun Jung-HoParent BrendanHambitzer FelixPeprah FrankKureshi Courtney T SLim Birkley SChang EugenaWalsh Michael JTello Julissa GAtajanova TavusShin HojeongPerkins CoreyKureshi RakeebMolina-Aponte YanirisDougan James MZuo ChongBrais LaurenClancy Thomas ECleary James MHornick Jason LHuffman Brandon MMancias Joseph DMolina GeorgeFairweather MarkNowak Jonathan APerez Kimberly JRubinson Douglas ASlater Sarahvan Dams RitchellWang JipingWolpin Brian MWong Kwok-KinSingh HarshabadAguirre Andrew JBaker DavidDougan MichaelDougan Stephanie K